Here are the DEF 14A proxy statements from Ocugen, Inc. (OCGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow OCGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OCGN filings page.
Ocugen, Inc. is asking stockholders to approve an amendment to its charter to increase authorized common stock by 250,000,000 shares, from 390,000,000 to 640,000,000, at a virtual special meeting on September 21, 2026. As of the July 27, 2026 record date, 339,110,401 common shares were outstanding, each entitled to one vote.
The Board cites needs for future equity financing, business combinations, and equity incentives, and to support potential share settlement of $130.0 million of 6.75% convertible senior notes due 2034, which require sufficient authorized but unissued shares by September 30, 2026. Ocugen acknowledges that issuing additional shares could dilute earnings per share and voting power and may have anti-takeover effects, though it states the proposal is not intended as a takeover defense. A second proposal would allow adjournment of the meeting to solicit additional proxies if votes for the share increase are initially insufficient.
Ocugen, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on four items: electing two Class III directors, ratifying PwC as auditor for 2026, approving executive pay on an advisory basis, and choosing the preferred frequency for future say‑on‑pay votes.
The proxy also highlights major 2025 progress in Ocugen’s modifier gene therapy pipeline, including completion of enrollment in the 140‑patient Phase 3 OCU400 liMeliGhT trial for retinitis pigmentosa, positive Phase 2 OCU410 data in geographic atrophy, and rapid enrollment in the Phase 2/3 GARDian3 trial of OCU410ST for Stargardt disease. Ocugen reports a strong balance sheet supported by a $22.5 million underwritten offering in January 2026 and $15 million from warrant exercises, and details a heavily performance‑based executive compensation program tied to clinical, financial, and talent objectives.